<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731301</url>
  </required_header>
  <id_info>
    <org_study_id>LIV01</org_study_id>
    <nct_id>NCT01731301</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)</brief_title>
  <official_title>A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Na√Øve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liver Institute of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chronic Liver Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Liver Institute of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. A maximally tolerated dose of ribavirin can be defined in each patient with ESRD
           undergoing hemodialysis.

        2. Patients with Chronic Hepatitis C Virus (HCV)and End-Stage Renal Disease
           (ESRD)undergoing hemodialysis will be able to tolerate and remain on treatment with
           peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.

        3. A significant percentage of patients with chronic HCV and ESRD undergoing hemodialysis
           can achieve rapid virologic response (RVR), extended virologic response (eRVR) and
           sustained virologic response (SVR) when treated with peginterferon alfa-2b, the
           maximally tolerated dose of ribavirin and boceprevir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ESRD will be treated with a dose escalation of ribavirin starting from 200 mg
      everyday (QD) to a maximal tolerated dose. Peginterferon will then be added. Ribavirin will
      be dose adjusted as needed. Boceprevir will then be added. Ribavirin will be dose adjusted as
      needed. Patients will be monitored for eRVR and SVR. The study end-point is eRVR.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who achieve eRVR at treatment week 28</measure>
    <time_frame>28 weeks</time_frame>
    <description>The primary end-point for evaluation will be the percentage of patients who achieve eRVR at treatment week 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>A. The ability to define the maximal tolerated dose of ribavirin. B. The ability to remain on peg-interferon alfa-2b, ribavirin and boceprevir for 24 weeks C. The percentage of patients who achieve SVR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Ribavirin, peginterferon, boceprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.</description>
    <arm_group_label>Ribavirin, peginterferon, boceprevir</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon</intervention_name>
    <description>After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.</description>
    <arm_group_label>Ribavirin, peginterferon, boceprevir</arm_group_label>
    <other_name>PegIntron, Rebetol and Victrelis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.</description>
    <arm_group_label>Ribavirin, peginterferon, boceprevir</arm_group_label>
    <other_name>Victralis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV defined by:

          -  A history of a positive anti-HCV or HCV RNA for &gt; 6 months or

          -  A liver biopsy demonstrating at least portal fibrosis

          -  HCV genotype 1

          -  No prior treatment with any interferon or peginterferon preparation

          -  ESRD undergoing hemodialysis for at least 6 months

          -  Willingness not to conceive a child during treatment and for 6 months following
             discontinuation of treatment.

        Exclusion Criteria:

          -  Histologic evidence of cirrhosis

          -  Any co-existent liver disease

          -  A platelet count &lt; 90,000

          -  A total white blood cell (WBC) &lt; 2.5

          -  An absolute neutrophil count &lt; 1.5

          -  Hemoglobin &lt; 11 gm/dl on Epoetin-alpha

          -  Positive test for anti-HIV

          -  Pregnancy of the patient or their intimate partner

          -  Women who are breast feeding

          -  Significant cardiovascular disease

          -  History of suicide intent, severe depression requiring hospitalization or significant
             psychiatric disease

          -  Malignancy within 5 years of enrollment except for squamous or basal cell skin cancer

          -  Co-existent immune disorder such as lupus, rheumatoid as arthritis, colitis, Crohns
             disease, sarcoidosis, etc.

          -  Any patient in the opinion of the investigator who would not be a satisfactory study
             candidate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell L Shiffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Institute of Virginia, Bon Secours Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell L Shiffman, MD</last_name>
    <phone>804-977-8920</phone>
    <email>mitchell_shiffman@bshsi.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April G. Long, NP</last_name>
    <phone>804-977-8920</phone>
    <email>april_long@bshsi.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitchell L Shiffman, MD</last_name>
      <phone>804-977-8920</phone>
      <email>mitchell_shiffman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell L Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2012</study_first_submitted>
  <study_first_submitted_qc>November 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>End stage renal disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Boceprevir</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Peg-interferon</keyword>
  <keyword>Triple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

